NASDAQ:ONCE - Spark Therapeutics Stock Price, Forecast & News

Spark Therapeutics trades on the NASDAQ under the ticker symbol "ONCE."

Spark Therapeutics Inc (NASDAQ:ONCE) released its quarterly earnings results on Tuesday, August, 7th. The biotechnology company reported ($0.77) earnings per share for the quarter, missing the Thomson Reuters' consensus estimate of ($0.43) by $0.34. The biotechnology company earned $25.19 million during the quarter, compared to analyst estimates of $29.44 million. Spark Therapeutics had a negative net margin of 358.41% and a negative return on equity of 59.10%. View Spark Therapeutics' Earnings History.

3 brokerages have issued twelve-month price targets for Spark Therapeutics' shares. Their forecasts range from $114.50 to $115.00. On average, they anticipate Spark Therapeutics' stock price to reach $114.75 in the next twelve months. This suggests a possible upside of 1.0% from the stock's current price. View Analyst Price Targets for Spark Therapeutics.

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Spark Therapeutics in the last year. There are currently 3 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Spark Therapeutics.

Media headlines about ONCE stock have been trending very negative this week, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of media coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Spark Therapeutics earned a daily sentiment score of -3.5 on InfoTrie's scale. They also assigned news articles about the biotechnology company a news buzz of 10.0 out of 10, indicating that recent media coverage is extremely likely to have an impact on the company's share price in the next few days. View News Stories for Spark Therapeutics.

Some companies that are related to Spark Therapeutics include NOVOZYMES A/S/S (NVZMY), Moderna (MRNA), Neurocrine Biosciences (NBIX), Qiagen (QGEN), BioNTech (BNTX), BIO-TECHNE (TECH), argenx (ARGX), Acceleron Pharma (XLRN), China Biologic Products (CBPO), Repligen (RGEN), Iovance Biotherapeutics (IOVA), Ablynx (ABLYF), bluebird bio (BLUE), Adaptive Biotechnologies (ADPT) and Allogene Therapeutics (ALLO).

Based on aggregate information from My MarketBeat watchlists, some companies that other Spark Therapeutics investors own include Brainstorm Cell Therapeutics (BCLI), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Gilead Sciences (GILD), AbbVie (ABBV), Exelixis (EXEL), BioMarin Pharmaceutical (BMRN), Celgene (CELG) and Netflix (NFLX).

(ONCE) raised $88 million in an initial public offering on Friday, January 30th 2015. The company issued 5,500,000 shares at a price of $15.00-$17.00 per share. J.P. Morgan and Credit Suisse served as the underwriters for the IPO and Cowen and Company and Sanford C. Bernstein were co-managers.

Shares of ONCE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

One share of ONCE stock can currently be purchased for approximately $113.57.

Spark Therapeutics has a market capitalization of $4.37 billion and generates $64.72 million in revenue each year. The biotechnology company earns $-78,820,000.00 in net income (profit) each year or ($2.11) on an earnings per share basis. Spark Therapeutics employs 368 workers across the globe.View Additional Information About Spark Therapeutics.

The official website for Spark Therapeutics is http://www.sparktx.com/.

Spark Therapeutics' mailing address is 3737 MARKET STREET SUITE 1300, PHILADELPHIA PA, 19104. The biotechnology company can be reached via phone at 888-772-7560 or via email at [email protected]